NFKB1 and COVID-19: Nevertheless, acalabrutinib (a tyrosine kinase inhibitor) and selinexor (acting through deactivation of NF-κB signaling) have been investigated in clinical trials for COVID-19 therapy and chloroquine and hydroxychloroquine have been approved by the US FDA for SARS-CoV-2 patients.